Healthcare Industry News: triglycerides
News Release - July 12, 2013
American Association Of Clinical Endocrinologists (AACE) Endorses Measurement Of Low-Density Lipoprotein Particle (LDL-P) NumberConsensus Statement Validates LDL-P Measurement by Nuclear Magnetic Resonance (NMR) in Patients with Diabetes to Reduce Risk of Cardiovascular Disease
RALEIGH, N.C., July 12, 2013 -- (Healthcare Sales & Marketing Network) -- LipoScience, Inc. (LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced that the American Association of Clinical Endocrinologists (AACE) has endorsed the measurement of low-density lipoprotein particles (LDL-P) as part of a management strategy to reduce the risk of cardiovascular disease (CVD) in patients with diabetes.
The recommendation to measure LDL-P by NMR appears in the AACE's Comprehensive Diabetes Management Algorithm 2013 Consensus Statement, published in a supplement to the May/June issue of Endocrine Practice. The consensus statement cites expert opinion that LDL-P "must be recognized and included in treatment recommendations," noting that patients with type 2 diabetes, insulin resistance, metabolic syndrome, and/or hypertriglyceridemia (elevated triglycerides) are the most likely populations to have persistently elevated LDL-P, even when low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) are at goal levels.
In presenting a new algorithm for the comprehensive management of persons with type 2 diabetes, the AACE consensus statement incorporates a CVD Risk Factor Modifications Algorithm that specifies desirable levels of LDL-P in at-risk patients. For patients at moderate risk of CVD (age younger than 40 years and/or no major risk factors aside from diabetes), an LDL-P level of less than 1200 nanomoles per liter (nmol/L) is considered desirable. For patients at high risk of CVD (diabetes plus one or more major risk factor, such as hypertension, family history, low HDL-C, or smoking), the desirable LDL-P level is less than 1000 nmol/L, according to the algorithm.
"The AACE consensus statement reflects the growing recognition of low-density lipoprotein particle measurement by NMR as an important risk management tool in patients with diabetes and other cardiovascular risk factors," stated Richard O. Brajer, chief executive officer of LipoScience. "The endorsement of such a respected organization supports our vision of widespread adoption of LDL-P testing for CVD management."
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfileŽ test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, VanteraŽ, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company's expectations for the future demand for its products and the factors that drive such demand. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Further information on potential factors and other risks that could affect the Company's business and operating results is included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at http://investor.liposcience.com/. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.